Healthcare provider profile · identity verified

Michael Charles Ampelas, DO

Family Practice · FORT WORTH, TX · NPI 1992753818

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	307	97
Amlodipine Besylate	Amlodipine Besylate	224	69
Losartan Potassium	Losartan Potassium	202	69
Rosuvastatin Calcium	Rosuvastatin Calcium	197	66
Levothyroxine Sodium	Levothyroxine Sodium	172	55
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	154	23
Gabapentin	Gabapentin	146	44
Pregabalin	Pregabalin	137	30
Metformin Hcl	Metformin Hcl	136	41
Lisinopril	Lisinopril	135	43
Tamsulosin Hcl	Tamsulosin Hcl	131	41
Trazodone Hcl	Trazodone Hcl	122	39
Montelukast Sodium	Montelukast Sodium	121	40
Metoprolol Succinate	Metoprolol Succinate	119	40
Simvastatin	Simvastatin	107	32
Pantoprazole Sodium	Pantoprazole Sodium	104	37
Alprazolam	Alprazolam	102	28
Hydrochlorothiazide	Hydrochlorothiazide	94	33
Omeprazole	Omeprazole	93	36
Celecoxib	Celecoxib	91	25
Fluticasone Propionate	Fluticasone Propionate	88	29
Albuterol Sulfate Hfa	Albuterol Sulfate	74	37
Carvedilol	Carvedilol	69	20
Metoprolol Tartrate	Metoprolol Tartrate	65	24
Furosemide	Furosemide	63	20
Prednisone	Prednisone	59	48
Sertraline Hcl	Sertraline Hcl	59	19
Eliquis	Apixaban	57	16
Zolpidem Tartrate	Zolpidem Tartrate	56	suppressed
Allopurinol	Allopurinol	55	16
Buspirone Hcl	Buspirone Hcl	55	15
Tramadol Hcl	Tramadol Hcl	48	16
Venlafaxine Hcl Er	Venlafaxine Hcl	48	14
Clopidogrel	Clopidogrel Bisulfate	44	14
Duloxetine Hcl	Duloxetine Hcl	43	14
Meloxicam	Meloxicam	43	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	12
Jardiance	Empagliflozin	40	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	40	15
Donepezil Hcl	Donepezil Hcl	39	12
Escitalopram Oxalate	Escitalopram Oxalate	39	13
Methocarbamol	Methocarbamol	39	15
Mirtazapine	Mirtazapine	39	11
Olmesartan Medoxomil	Olmesartan Medoxomil	38	11
Potassium Chloride	Potassium Chloride	37	18
Spironolactone	Spironolactone	37	14
Tizanidine Hcl	Tizanidine Hcl	37	11
Memantine Hcl	Memantine Hcl	36	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	35	12
Nifedipine Er	Nifedipine	35	12
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	34	suppressed
Ropinirole Hcl	Ropinirole Hcl	33	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	31	suppressed
Bupropion Xl	Bupropion Hcl	30	12
Clonazepam	Clonazepam	30	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	30	suppressed
Acyclovir	Acyclovir	29	suppressed
Metformin Hcl Er	Metformin Hcl	29	suppressed
Diazepam	Diazepam	28	suppressed
Pravastatin Sodium	Pravastatin Sodium	28	suppressed
Hydralazine Hcl	Hydralazine Hcl	27	suppressed
Valsartan	Valsartan	26	suppressed
Glipizide Er	Glipizide	25	suppressed
Xarelto	Rivaroxaban	25	suppressed
Ipratropium Bromide	Ipratropium Bromide	23	suppressed
Ozempic	Semaglutide	23	suppressed
Finasteride	Finasteride	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Promethazine Hcl	Promethazine Hcl	22	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Diclofenac Sodium	Diclofenac Sodium	21	suppressed
Ezetimibe	Ezetimibe	21	suppressed
Hydrocortisone	Hydrocortisone	21	suppressed
Mounjaro	Tirzepatide	21	suppressed
Atenolol	Atenolol	20	suppressed
Estradiol	Estradiol	20	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	20	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	19	suppressed
Temazepam	Temazepam	19	suppressed
Testosterone Cypionate	Testosterone Cypionate	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Azithromycin	Azithromycin	16	14
Baclofen	Baclofen	16	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	16	14
Droplet Pen Needle	Pen Needle, Diabetic	16	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	15
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Naproxen	Naproxen	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Sucralfate	Sucralfate	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Ramipril	Ramipril	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Xtampza Er	Oxycodone Myristate	13	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	12	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	12	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	12	suppressed
Dilantin	Phenytoin Sodium Extended	12	suppressed
Estradiol (Twice Weekly)	Estradiol	12	suppressed
Famotidine	Famotidine	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Progesterone	Progesterone, Micronized	11	suppressed
Testosterone	Testosterone	11	suppressed
Torsemide	Torsemide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error